FORT WORTH, Texas — A lawsuit that could restrict access to mifepristone across the United States has been paused while the Food and Drug Administration reviews the medicine’s safety.
US District Judge Reed O’Connor stayed the case until 1 December 2026 or the completion of the FDA review, whichever occurs first. The order, reported by Reuters on 1 September, leaves current access rules in place during the pause.
Florida and Texas filed the case in December 2025. They challenge the FDA’s original 2000 approval of mifepristone as well as later decisions that expanded access, including telehealth prescribing and delivery by mail. The states seek changes that could operate nationally, including in jurisdictions where abortion remains legal.
O’Connor rejected requests from manufacturers GenBioPro and Danco Laboratories to dismiss the lawsuit. That means the pause is not a victory on the merits for either side; it simply postpones the next stage while the regulator conducts its assessment.
Mifepristone is used with misoprostol for medication abortion in early pregnancy and is also used in miscarriage care. Medication accounts for more than 60% of US abortions, according to figures cited by Reuters, so even an administrative change can affect clinics, pharmacies and patients far beyond the two plaintiff states.
The FDA and major medical organisations maintain that mifepristone is safe and effective when used as directed and that serious adverse events are rare. The states argue that federal rules undermine their abortion restrictions and expose them to costs associated with emergency care.
Those claims will require evidence, not political repetition. A safety review should publish its methodology, data sources, conflict safeguards and explanation for any change. It should distinguish complications caused by the medicine from unrelated pregnancy events and from harms created when patients cannot obtain timely care.
For patients, the immediate instruction is practical: do not assume the drug has been banned. Availability still depends on federal rules, state law and individual providers, and those conditions can change quickly. People seeking care should use reputable clinical or legal-information services rather than social-media claims.
The case also illustrates why regulatory litigation has become a second front after the Supreme Court ended the federal constitutional right to abortion in 2022. States can attempt to project their restrictions beyond their borders by challenging nationwide FDA decisions.
The stay creates time, not certainty. Its significance will depend on whether the FDA’s review remains scientifically independent—and whether the court treats evidence gathered over decades as stronger than a state’s effort to control access elsewhere.
Join the discussion